Skip to main content
Top
Published in: Endocrine 2/2009

01-04-2009 | Original Paper

Fructose-rich diet-induced abdominal adipose tissue endocrine dysfunction in normal male rats

Authors: Ana Alzamendi, Andrés Giovambattista, Agustina Raschia, Viviana Madrid, Rolf C. Gaillard, Oscar Rebolledo, Juan J. Gagliardino, Eduardo Spinedi

Published in: Endocrine | Issue 2/2009

Login to get access

Abstract

We have currently studied the changes induced by administration of a fructose-rich diet (FRD) to normal rats in the mass and the endocrine function of abdominal (omental) adipose tissue (AAT). Rats were fed ad libitum a standard commercial chow and tap water, either alone (control diet, CD) or containing fructose (10%, w/vol) (FRD). Three weeks after treatment, circulating metabolic markers and leptin release from adipocytes of AAT were measured. Plasma free fatty acids (FFAs), leptin, adiponectin, and plasminogen activator inhibitor-1 (PAI-1) levels were significantly higher in FRD than in CD rats. AAT mass was greater in FRD than in CD rats and their adipocytes were larger, they secreted more leptin and showed impaired insulin sensitivity. While leptin mRNA expression increased in AAT from FRD rats, gene expression of insulin receptor substrate, IRS1 and IRS2 was significantly reduced. Our study demonstrates that administration of a FRD significantly affects insulin sensitivity and several AAT endocrine/metabolic functions. These alterations could be part of a network of interacting abnormalities triggered by FRD-induced oxidative stress at the AAT level. In view of the impaired glucose tolerance observed in FRD rats, these alterations could play a key role in both the development of metabolic syndrome (MS) and β-cell failure.
Literature
1.
go back to reference S.S. Elliott, N.L. Keim, J.S. Stern, K. Teff, P.J. Havel, Am. J. Nutr. 76, 911–922 (2002) S.S. Elliott, N.L. Keim, J.S. Stern, K. Teff, P.J. Havel, Am. J. Nutr. 76, 911–922 (2002)
2.
go back to reference L.S. Kantor, J.N. Variyam, J.E. Allshouse, J.J. Putnam, B.H. Lin, J. Nutr. 131, 473S–486S (2001)PubMed L.S. Kantor, J.N. Variyam, J.E. Allshouse, J.J. Putnam, B.H. Lin, J. Nutr. 131, 473S–486S (2001)PubMed
3.
go back to reference G.A. Bray, S.J. Nielsen, B.M. Popkin, Am. J. Clin. Nutr. 79, 537–543 (2004)PubMed G.A. Bray, S.J. Nielsen, B.M. Popkin, Am. J. Clin. Nutr. 79, 537–543 (2004)PubMed
7.
go back to reference O.R. Rebolledo, C.A. Marra, A. Raschia, S. Rodriguez, J.J. Gagliardino, Horm. Metab. Res. 40, 794–800 (2008)CrossRefPubMed O.R. Rebolledo, C.A. Marra, A. Raschia, S. Rodriguez, J.J. Gagliardino, Horm. Metab. Res. 40, 794–800 (2008)CrossRefPubMed
8.
go back to reference T.J. Guzik, D. Mangalat, R. Korbut, J. Physiol. Pharmacol. 57, 505–528 (2006)PubMed T.J. Guzik, D. Mangalat, R. Korbut, J. Physiol. Pharmacol. 57, 505–528 (2006)PubMed
9.
go back to reference R. Miatello, M. Vázquez, N. Renna, M. Cruzado, A.P. Zumino, N. Risler, Am. J. Hypertens. 18, 864–870 (2005)CrossRefPubMed R. Miatello, M. Vázquez, N. Renna, M. Cruzado, A.P. Zumino, N. Risler, Am. J. Hypertens. 18, 864–870 (2005)CrossRefPubMed
10.
11.
go back to reference U. Smith, M. Axelsen, E. Carvalho, B. Eliasson, P.A. Jansson, C. Wesslau, Ann. N. Y. Acad. Sci. 892, 119–126 (1999)CrossRefPubMed U. Smith, M. Axelsen, E. Carvalho, B. Eliasson, P.A. Jansson, C. Wesslau, Ann. N. Y. Acad. Sci. 892, 119–126 (1999)CrossRefPubMed
13.
14.
go back to reference A. Soria, M.E. D’Alessandro, Y.B. Lombardo, J. Appl. Physiol. 91, 2109–2116 (2001)PubMed A. Soria, M.E. D’Alessandro, Y.B. Lombardo, J. Appl. Physiol. 91, 2109–2116 (2001)PubMed
15.
go back to reference C. Couillard, P. Mauriège, P. Imbeault et al., Int. J. Obes. Relat. Metab. Disord. 24, 782–788 (2000)CrossRefPubMed C. Couillard, P. Mauriège, P. Imbeault et al., Int. J. Obes. Relat. Metab. Disord. 24, 782–788 (2000)CrossRefPubMed
17.
go back to reference F. Krempler, E. Hell, C. Winkler, D. Breban, W. Patsch, Arterioscler. Thromb. Vasc. Biol. 18, 1686–1690 (1998)PubMed F. Krempler, E. Hell, C. Winkler, D. Breban, W. Patsch, Arterioscler. Thromb. Vasc. Biol. 18, 1686–1690 (1998)PubMed
18.
22.
23.
go back to reference P. Eriksson, S. Reynisdottir, F. Lönnqvist, V. Stemme, A. Hamsten, P. Arner, Diabetologia 41, 65–71 (1998)CrossRefPubMed P. Eriksson, S. Reynisdottir, F. Lönnqvist, V. Stemme, A. Hamsten, P. Arner, Diabetologia 41, 65–71 (1998)CrossRefPubMed
24.
go back to reference S. Furukawa, T. Fujita, M. Shimabukuro et al., J. Clin. Invest. 114, 1752–1761 (2004)PubMed S. Furukawa, T. Fujita, M. Shimabukuro et al., J. Clin. Invest. 114, 1752–1761 (2004)PubMed
26.
go back to reference I. Kharroubi, L. Ladriere, A.K. Cardozo, Z. Dogusan, M. Cnop, D.L. Eizirik, Endocrinology 145, 5087–5096 (2004)CrossRefPubMed I. Kharroubi, L. Ladriere, A.K. Cardozo, Z. Dogusan, M. Cnop, D.L. Eizirik, Endocrinology 145, 5087–5096 (2004)CrossRefPubMed
28.
go back to reference A. Giovambattista, A.N. Chisari, R.C. Gaillard, E. Spinedi, Neuroendocrinology 72, 341–349 (2000)CrossRefPubMed A. Giovambattista, A.N. Chisari, R.C. Gaillard, E. Spinedi, Neuroendocrinology 72, 341–349 (2000)CrossRefPubMed
29.
go back to reference G. Moreno, M. Perelló, G. Camihort et al., Int. J. Obes. 30, 73–82 (2006)CrossRef G. Moreno, M. Perelló, G. Camihort et al., Int. J. Obes. 30, 73–82 (2006)CrossRef
30.
go back to reference A. Giovambattista, J. Piermaría, M.O. Suescun, R.S. Calandra, R.C. Gaillard, E. Spinedi, Obesity 14, 19–27 (2006)CrossRefPubMed A. Giovambattista, J. Piermaría, M.O. Suescun, R.S. Calandra, R.C. Gaillard, E. Spinedi, Obesity 14, 19–27 (2006)CrossRefPubMed
33.
go back to reference W.D. McElroy, C.P. Swanson (eds.), Biostatistical Analysis (Prentice-Hall-Englewood Cliffs, New Jersey, 1974) W.D. McElroy, C.P. Swanson (eds.), Biostatistical Analysis (Prentice-Hall-Englewood Cliffs, New Jersey, 1974)
Metadata
Title
Fructose-rich diet-induced abdominal adipose tissue endocrine dysfunction in normal male rats
Authors
Ana Alzamendi
Andrés Giovambattista
Agustina Raschia
Viviana Madrid
Rolf C. Gaillard
Oscar Rebolledo
Juan J. Gagliardino
Eduardo Spinedi
Publication date
01-04-2009
Publisher
Springer US
Published in
Endocrine / Issue 2/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-008-9143-1

Other articles of this Issue 2/2009

Endocrine 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine